Projects per year
Personal profile
Biography
Professor Ian Davis MBBS(Hons) PhD FRACP FAChPM FAHMS GAICD is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He is an NHMRC Leadership Fellow L3 (2023-2027). He is an Affiliate Professor of Deakin University, adjunct Associate Professor of the University of Melbourne, an Associate of the University of Sydney, Honorary Professorial Fellow with The George Institute, and Adjunct Professor of the University of New South Wales. His primary clinical interests are in urologic cancers, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Medical & Scientific Committee and of the Standing Subcommittee on Research for the Cancer Council Victoria. He founded the Urologic Oncology Group of the Clinical Oncology Society of Australia (COSA), is a member of COSA Council, and previously a COSA Board director. Prof Davis is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP). He is chair of the ANZUP Board and of its Scientific Advisory Committee. Prof Davis has published over 300 papers with over 17,000 citations, attracted over $30M in grant funding, and been involved in over 200 clinical trials for which he was global or site Principal Investigator in over 130.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Cancer immunology, PhD, Interleukin-4 as an anticancer cytokine, University of Melbourne
Award Date: 1 May 1997
Medicine, MB BS (First class honours), MONASH UNIVERSITY
Award Date: 7 Dec 1983
External positions
Professor of Medicine, Eastern Health
1 Jul 2012 → …
Chair, ANZUP Cancer Trials Group Limited
8 Oct 2008 → …
Research area keywords
- Oncology
- Cancer Immunology
- Immunotherapy
- Genitourinary cancers
- VIC
- Bladder cancer
- Renal cell carcinoma
- Germ cell cancer
- Melanoma
- Clinical research
- Clinical trials
- Cancer biology
Collaborations and top research areas from the last five years
-
ENZAMET QOL-FI: Developing a Quality of Life-derived Frailty Index and assessing the effects of Enzalutamide and Comprehensive Geriatric Assessment on Frailty and Resilience in Prostate Cancer and Older Cancer Patients: insights from the ENZAMET and INTEGERATE randomised controlled trials
Soo, K. (Primary Chief Investigator (PCI)) & Davis, I. (Supervisor)
ANZUP Cancer Trials Group Limited
1/10/24 → 30/09/26
Project: Research
-
More accurate disease assessment and improved clinical decision-making for patients with urothelial cancers
Davis, I. (Primary Chief Investigator (PCI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/23 → 31/12/27
Project: Research
-
Integrative Molecular Characterization and Biomarker Validation in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Hamid, A. (Primary Chief Investigator (PCI)), Sweeney, C. J. (Chief Investigator (CI)), Corcoran, N. (Chief Investigator (CI)), Davis, I. (Chief Investigator (CI)), van Allen, E. M. (Chief Investigator (CI)), Attard, G. (Chief Investigator (CI)), Azad, A. (Chief Investigator (CI)) & Wang, X. V. (Chief Investigator (CI))
1/09/21 → 31/08/25
Project: Research
-
Bio-Rad CFX Opus 96 Real-Time PCR System
Davis, I. (Primary Chief Investigator (PCI)), Sengupta, S. (Chief Investigator (CI)) & Sluka, P. (Chief Investigator (CI))
1/10/21 → 31/12/22
Project: Research
-
Actionable data for clinicians and external accreditors in support of quality care provision and continuous accreditation.
Wybrow, M. (Primary Chief Investigator (PCI)), Taniar, D. (Chief Investigator (CI)), Davis, I. (Chief Investigator (CI)), Kokai, Z. (Partner Investigator (PI)), Luxford, K. (Partner Investigator (PI)) & Board, N. (Partner Investigator (PI))
Monash University – Internal Faculty Contribution
1/04/21 → 31/03/25
Project: Research
-
…But Words Will Never Hurt Me
Davis, I. D., Anton, A. & Kwan, E. M., Mar 2025, In: European Urology. 87, 3, p. 289-291 3 p.Research output: Contribution to journal › Editorial › Other › peer-review
-
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Gedye, C., Rutherford, N. K., Sandhu, S., Kumar, A. R., Pook, D., Ramdave, S. & Nadebaum, D. P. & 20 others, , May 2024, In: The Lancet Oncology. 25, 5, p. 563-571 9 p.Research output: Contribution to journal › Article › Research › peer-review
49 Citations (Scopus) -
Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: Patient experiences
Viljoen, B., Hofman, M. S., Chambers, S. K., Dunn, J., Dhillon, H., Davis, I. D. & Ralph, N., Nov 2024, In: BMJ Supportive & Palliative Care. 14, e2, p. e2177-e2183 7 p.Research output: Contribution to journal › Article › Research › peer-review
4 Citations (Scopus) -
A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity
Li, M., Nandurkar, R., Toniolo, J., Davis, I. D. & Sengupta, S., 4 Mar 2024, In: World Journal of Urology. 42, 1, 7 p., 115.Research output: Contribution to journal › Article › Research › peer-review
-
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Conduit, C., Davis, I. D., Goh, J. C., Kichenadasse, G., Gurney, H., Harris, C. A., Pook, D., Krieger, L., Parnis, F., Underhill, C., Adams, D., Roncolato, F., Joshua, A., Ferguson, T., Prithviraj, P., Morris, M., Harrison, M., Begbie, S., Hovey, E. & George, M. & 5 others, , Feb 2024, In: BJU International. 133, S3, p. 57-67 11 p.Research output: Contribution to journal › Article › Research › peer-review
4 Citations (Scopus)